pioglitazone has been researched along with Adenocarcinoma, Basal Cell in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB." | 5.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016) |
| " We investigated the biological effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's adenocarcinoma cells in vitro and in vivo." | 3.75 | Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo. ( Al-Taie, OH; Barthelmes, HU; Graf, T; Illert, B; Katzenberger, T; Kraus, MR; Mörk, H; Scheurlen, M; Seufert, J, 2009) |
| " The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma." | 3.72 | Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. ( Casini, A; Ceni, E; Crabb, DW; Galli, A; Grappone, C; Mello, T; Milani, S; Salzano, R; Surrenti, C; Surrenti, E, 2004) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB." | 1.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016) |
| "When pioglitazone was administered beginning 8 weeks after the first carcinogen treatment when microscopic adenomas already existed, pioglitazone significantly inhibited tumor load (sum of tumor volume per lung in average) by 64% (P < 0." | 1.36 | Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. ( James, M; Lu, Y; Lubet, RA; Szabo, E; Wang, Y; Wen, W; You, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Suzuki, S | 1 |
| Mori, Y | 1 |
| Nagano, A | 1 |
| Naiki-Ito, A | 1 |
| Kato, H | 1 |
| Nagayasu, Y | 1 |
| Kobayashi, M | 1 |
| Kuno, T | 1 |
| Takahashi, S | 1 |
| Al-Taie, OH | 1 |
| Graf, T | 1 |
| Illert, B | 1 |
| Katzenberger, T | 1 |
| Mörk, H | 1 |
| Kraus, MR | 1 |
| Barthelmes, HU | 1 |
| Scheurlen, M | 1 |
| Seufert, J | 1 |
| Wang, Y | 1 |
| James, M | 1 |
| Wen, W | 1 |
| Lu, Y | 1 |
| Szabo, E | 1 |
| Lubet, RA | 1 |
| You, M | 1 |
| Li, H | 1 |
| Sorenson, AL | 1 |
| Poczobutt, J | 1 |
| Amin, J | 1 |
| Joyal, T | 1 |
| Sullivan, T | 1 |
| Crossno, JT | 1 |
| Weiser-Evans, MC | 1 |
| Nemenoff, RA | 1 |
| Galli, A | 1 |
| Ceni, E | 1 |
| Crabb, DW | 1 |
| Mello, T | 1 |
| Salzano, R | 1 |
| Grappone, C | 1 |
| Milani, S | 1 |
| Surrenti, E | 1 |
| Surrenti, C | 1 |
| Casini, A | 1 |
1 review available for pioglitazone and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
5 other studies available for pioglitazone and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.
Topics: Adenocarcinoma; Animals; Body Weight; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease | 2016 |
Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Line, Tumor; Cell Proliferation; Esophag | 2009 |
Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinogens; Carcinoma, Squamous Cell; Chemopreventi | 2010 |
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
Topics: Adenocarcinoma; Animals; Bone Marrow; Coculture Techniques; Disease Progression; Fluorescent Antibod | 2011 |
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cell Division; DNA, Neoplasm; Dose-Response Rela | 2004 |